Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Metreleptin
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
Details : Metreleptin is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lipodystrophy, Congenital Generalized.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 19, 2019
Lead Product(s) : Metreleptin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lomitapide
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2016
Lead Product(s) : Lomitapide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lomitapide
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2014
Lead Product(s) : Lomitapide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.
Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2014
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2014
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled
Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2014
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2013
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 04, 2013
Lead Product(s) : Lomitapide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lomitapide
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : University of Pennsylvania | Doris Duke Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2012
Lead Product(s) : Lomitapide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : University of Pennsylvania | Doris Duke Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
